These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11682352)

  • 21. Effect of exercise on reactivity and motor behaviour in patients with Parkinson's disease.
    Müller T; Muhlack S
    J Neurol Neurosurg Psychiatry; 2010 Jul; 81(7):747-53. PubMed ID: 20478845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Madopar in the complex therapy of ischemic insult].
    Odinak MM; Vozniuk IA; Kovalenko PA; Lobzin SV; Ianishevskiĭ SN
    Voen Med Zh; 2005 Jan; 326(1):35-9. PubMed ID: 15754768
    [No Abstract]   [Full Text] [Related]  

  • 23. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
    Bachmann CG; Zapf A; Brunner E; Trenkwalder C
    Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
    Rinne UK
    Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficiency of new forms of madopar in Parkinson's disease].
    Vendrova MI; Sadekov RA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(12):46-8. PubMed ID: 11195538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The first miracle in neurodegenerative disease: the discovery of oral levodopa.
    Kordower JH; Goetz CG
    Brain Res Bull; 1999; 50(5-6):377-8. PubMed ID: 10643443
    [No Abstract]   [Full Text] [Related]  

  • 28. [Current possibilities of quality of life improvement in the late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(3):94-100. PubMed ID: 26171484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled release form of madopar in parkinsonian patients with advanced disease and marked fluctuations in motor performance.
    Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO
    Acta Neurol Scand; 1988 May; 77(5):422-5. PubMed ID: 3046226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
    Crevoisier C; Monreal A; Metzger B; Nilsen T
    Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.
    Weller C; O'Neill CJ; Charlett A; Bowes SG; Purkiss A; Nicholson PW; Dobbs RJ; Dobbs SM
    Br J Clin Pharmacol; 1993 Apr; 35(4):379-85. PubMed ID: 8485018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
    Parkinson Study Group
    JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease.
    Herz DM; Siebner HR; Hulme OJ; Florin E; Christensen MS; Timmermann L
    Neuroimage; 2014 Apr; 90():15-23. PubMed ID: 24269570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
    J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Deleu D; Hanssens Y
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16721952
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
    Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
    J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
    Chouza C; Romero S; de Medina O; Aljanati R; Scarmelli A; Caamano JL; Gonzales Panizza V
    Eur Neurol; 1987; 27 Suppl 1():59-67. PubMed ID: 3428309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
    Muhlack S; Woitalla D; Welnic J; Twiehaus S; Przuntek H; Müller T
    Neurosci Lett; 2004 Jun; 363(3):284-7. PubMed ID: 15182961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity enhances dopaminergic long-duration response in Parkinson disease.
    Kang UJ; Auinger P;
    Neurology; 2012 Apr; 78(15):1146-9. PubMed ID: 22459675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model.
    Decamp E; Schneider JS
    Brain Res; 2009 Mar; 1262():109-14. PubMed ID: 19368843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.